Orexigen Therapeutics, Inc. v.

990 F.3d 748
CourtCourt of Appeals for the Third Circuit
DecidedMarch 19, 2021
Docket20-1136
StatusPublished
Cited by9 cases

This text of 990 F.3d 748 (Orexigen Therapeutics, Inc. v.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Orexigen Therapeutics, Inc. v., 990 F.3d 748 (3d Cir. 2021).

Opinion

PRECEDENTIAL UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT _____________

No. 20-1136 _____________

IN RE: OREXIGEN THERAPEUTICS, INC., Debtor

MCKESSON CORPORATION; RXC ACQUISITION COMPANY, Appellants _______________

On Appeal from the United States District Court for the District of Delaware (D.C. No.1-18-cv-01873) District Judge: Hon. Colm F. Connolly _____________

Argued November 17, 2020

Before: JORDAN, KRAUSE, and RESTREPO, Circuit Judges

(Filed: March 19, 2021) _______________ Jeffrey K. Garfinkle [ARGUED] Daniel H. Slate BUCHALTER 3131 Princeton Pike 18400 Von Karman Avenue, Suite 800 Irvine, CA 92612-0514

Kurt F. Gwynne Jason D. Angelo REED SMITH LLP 1201 North Market Street, Suite 1500 Wilmington, DE 19801 Counsel for Appellants

Eric Winston Bennett Murphy [ARGUED] Razmig Izakelian QUINN EMANUEL URQUHART & SULLIVAN LLP 865 S. Figueroa Street, 10th Floor Los Angeles, CA, 90017

Christopher M. Samis L. Katherine Good POTTER ANDERSON & CORROON LLP Christopher M. Samis The Renaissance Centre 405 North King Street, Suite 500 Wilmington, DE 19801 Counsel for Appellees _______________

OPINION OF THE COURT _______________

2 JORDAN, Circuit Judge.

This dispute turns on the meaning of the word “mutual” in the provision of the Bankruptcy Code that allows parties to invoke setoff rights when the debts they owe one another are mutual. See 11 U.S.C. § 553.

McKesson Corporation, Inc. (“McKesson”) and Orexigen Therapeutics, Inc. (“Orexigen”) agreed to a pharmaceutical distribution deal and included a provision in their contract whereby McKesson, as distributor of the drug, could reduce what it owed to Orexigen, the drug manufacturer, by any amount that Orexigen owed to McKesson or any McKesson subsidiary. Shortly thereafter, one of those subsidiaries, McKesson Patient Relationship Solutions (“MPRS”),1 separately agreed to help Orexigen with a consumer discount program by advancing cash to pharmacies, with Orexigen then obligated to reimburse MPRS. Later, when Orexigen filed for bankruptcy, it owed MPRS approximately $9 million, and McKesson owed Orexigen approximately $7 million. The Bankruptcy Court and the District Court rejected McKesson’s request to set off its debt by the amount Orexigen owed MPRS, which would have reduced MPRS’s claim to approximately $2 million and McKesson’s debt to zero. Both courts held that what McKesson wanted was a triangular setoff, not a mutual one, and thus was not the kind allowable under § 553 of the Bankruptcy Code. We agree and will affirm.

1 MPRS later merged into RxC Acquisition Company, a named Appellant, which is also a subsidiary of McKesson.

3 I. BACKGROUND

Orexigen was a publicly traded pharmaceutical company whose only commercial product was a weight management drug called Contrave. On June 9, 2016, Orexigen entered into a “Distribution Agreement” with McKesson, whereby Orexigen sold Contrave to McKesson, and McKesson in turn provided the drug to pharmacies. Included in the Distribution Agreement was a “Setoff Provision” that permitted “each of [McKesson] and its affiliates … to set-off, recoup and apply any amounts owed by it to [Orexigen’s] affiliates against any [and] all amounts owed by [Orexigen] or its affiliates to any of [McKesson] or its affiliates.” (App. at 13.)

Separate from the Distribution Agreement, MPRS and Orexigen entered into a “Services Agreement” on July 5, 2016. Under the Services Agreement, MPRS managed a customer loyalty program for Orexigen, pursuant to which patients would receive price discounts from pharmacies. MPRS would advance funds to pharmacies selling Contrave, with reimbursement arriving later from Orexigen. The Distribution Agreement and Services Agreement did not reference, incorporate, or integrate one another, and the parties agree that McKesson and MPRS were distinct legal entities.

By the time Orexigen filed its petition for Chapter 11 relief on March 12, 2018 (the “Petition Date”), it owed MPRS approximately $9.1 million under the Services Agreement, and McKesson owed Orexigen some $6.9 million under the

4 Distribution Agreement.2 Had there been a setoff of those obligations pursuant to the Setoff Provision, Orexigen would have owed MPRS $2.2 million and McKesson would have owed Orexigen nothing.

On March 16, 2018, four days after the Petition Date, Orexigen filed a motion to sell substantially all of its assets for $75 million in cash. McKesson objected to the asset sale, and, following that objection, the parties negotiated for McKesson to pay the approximately $6.9 million receivable it owed to Orexigen, while Orexigen agreed to keep that sum segregated pending resolution of the setoff dispute.3

McKesson and MPRS then asked the Bankruptcy Court to decide their rights to the segregated funds under the Setoff Provision in the Distribution Agreement and § 553 of the Code.4 The Court rejected McKesson’s argument for a setoff

2 Orexigen says there is a dispute over the amount Orexigen owes MPRS, claiming the proof of claim only establishes $8,564,075.68 due. The Bankruptcy Court held, and we agree, that the precise amount is not material to the legal questions presented. 3 The segregated $6.9 million is currently held by Province, Inc., which, as the administrator of the bankruptcy estate, has taken control of Orexigen’s remaining assets pursuant to the confirmed liquidation plan. 4 Section 553 reads: “Except as otherwise provided in this section and in sections 362 and 363 of this title, this title does not affect any right of a creditor to offset a mutual debt owing by such creditor to the debtor that arose before the

5 because, while the Setoff Provision constituted an “enforceable contractual right allowing a parent and its subsidiary corporation to [e]ffect a prepetition triangular setoff under state law[,]” that relationship “does not supply the strict mutuality required in bankruptcy.” In re Orexigen Therapeutics, Inc., 596 B.R. 9, 12 (Bankr. D. Del. 2018).5

The Bankruptcy Court went on to discuss the meaning of mutuality, relying on its own precedent in a case called In re SemCrude to conclude that § 553 “is strictly construed against the party seeking setoff.” Id. at 17 (citing In re SemCrude, L.P., 399 B.R. 388, 396 (Bankr. D. Del. 2009) (citation omitted)). It held, as it had in SemCrude, that contracts cannot

commencement of the case under this title against a claim of such creditor against the debtor that arose before the commencement of the case[.]” 11 U.S.C. § 553(a). Three enumerated exceptions follow. Section 553 uses the terms “offset” and “setoff,” while the parties often use the term “setoff.” Viewing these as synonyms, we generally use the latter herein, as that is the language used in documents at issue in the case. 5 The Bankruptcy Court assumed without deciding that the parties had an enforceable prepetition right to setoff under California law. See In re Orexigen Therapeutics, Inc., 596 B.R. at 15. It noted that, although the parties disputed whether McKesson was a creditor within the meaning of § 553, they did not substantially brief the issue, so it deemed McKesson a creditor such that it could pursue its setoff claim, particularly in light of the parties’ stipulation to preserve the disputed assets. See id. at 16.

6 turn nonmutual debts into debts subject to setoff under the Code, as if they had been mutual. See id. at 18. The Court rejected McKesson’s argument that mutuality merely “identifies the state-law right that is thereby preserved unaffected in bankruptcy.” (Opening Br.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

UBS v. Lorenzo Esteva
Eleventh Circuit, 2025
Andrew B Zezas
D. New Jersey, 2023
Rams Associates, L.P. v.
Third Circuit, 2022
NIMOITYN
E.D. Pennsylvania, 2022
FRACTION v. JACKLILY, LLC
E.D. Pennsylvania, 2021
CARBALLEIRA v. BOND
D. New Jersey, 2021

Cite This Page — Counsel Stack

Bluebook (online)
990 F.3d 748, Counsel Stack Legal Research, https://law.counselstack.com/opinion/orexigen-therapeutics-inc-v-ca3-2021.